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Cell-to-cell interactions via gap junctional communication and connexon hemichannels are involved in the pathogenesis of
diabetes. Gap junctions are highly specialized transmembrane structures that are formed by connexon hemichannels, which are
further assembled from proteins called “connexins.” In this paper, we discuss current knowledge about connexins in diabetes. We
also discuss mechanisms of connexin inﬂuence and the role of individual connexins in various tissues and how these are aﬀected
in diabetes. Connexins may be a future target by both genetic and pharmacological approaches to develop treatments for the
treatment of diabetes and its complications.
1.Introduction
Morbidity and mortality caused by diabetes is of serious
concernworldwide.Globalprevalenceofdiabetesisexpected
to increase from 7.7% to 439 million by 2030 [1]. Diabetes
is a disorder characterised by multiple defects at both the
cellular and molecular levels in a wide variety of tissues.
Resulting tissue damage in diabetes is associated with inter-
actionsand“crosstalk”betweeninﬂammatoryandmetabolic
pathological processes such as endothelial dysfunction (via
VCAM-1, ICAM-1, E-selection, vWF), procoagulation (PAI-
1, ﬁbronectin, and P-selectin), and inﬂammation (TNFα,I L -
6, IL-1β,I L - 1 8 ,a n dC R P )[ 2]. Cell-to-cell interactions, via
gapjunctionalcommunicationandconnexonhemichannels,
are now thought to play an important role in the molecular
biology of diabetes. In this paper, we discuss current knowl-
edge about connexins (Cxs) and their role in various aspects
of diabetes.
2. GapJunctions, Connexons, and Connexins
Gap junctions are highly specialized structures, made up of
channels spanning adjacent cell membranes, leaving a 2–
4nm extracellular “gap,” hence their name [3, 4]. In
vertebrates, gap junction channels are assembled of trans-
membrane proteins called “connexins.” Cxs are commonly
described in terms of molecular mass (Cx43 represents the
Cx protein of 43kDa). Six Cx units oligomerize in the en-
doplasmic reticulum to form an annular hemichannel or
“connexon.” Cxs can interact structurally in various ways,
and connexons are regarded as homeric if the Cxs are of the
same type or heteromeric if they are of diﬀerent types. Sim-
ilarly,thegapjunctionalchannelsmaybeformedbyhomeric
or heteromeric connexons (see Figure 1). When the extracel-
lular portion of a connexon docks with connexon from an
opposing cell, a functional gap junction channel forms.
Tissue homeostasis is dependent on a complex system
of cell communication over long distances by endocrine
signalling, short distances via membrane signalling path-
ways (ion channels, G-protein coupled or tyrosine-kinase
receptors), and by cell-to-cell contact. Gap junctions allow
a unique form of communication; they mediate intracel-
lular signals by directly connecting adjacent cells. Their
purpose is to closely regulate the intracellular passage of
ions, nutrients, metabolites, second messengers, and small
biological molecules (up to 1000Da). The multiplicity of
isoforms and diﬀerent structural combinations determine
the biophysical permeation characteristics of a gap junction
channel. Aside from forming gap junctions, the connexon
hemichannels also provide a pathway for the release from
c e l l so fA T P ,g l u t a m a t e ,N A D +, and prostaglandin E2, which
act as paracrine messengers [5]. A dynamic cell-to-cell2 Cardiology Research and Practice
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Figure 1:Multiplelevelsofgapjunctionchannelstructure.Individ-
ualtransmembraneconnexins(colouredblueandorange)assemble
into hexamers called “connexon hemichannels.” Connexons from
two adjacent cells join to make a channel across two plasma
membranes (green), forming a “gap junction channel.”
communication is advantageous as it avoids the transport
mechanisms, ligand-receptor interactions, and dilutional
eﬀects associated with extracellular communication. A key
function of gap junctions is sharing of metabolic demands
across cells and tissues [6]. They are also of critical impor-
t a n c ei nc e l ld i ﬀerentiation, adhesion, and apoptosis, and
theyhaveregulatoryrolesinembryonicdevelopment,synap-
tic transmission, immune response, and carcinogenesis.
Cxs are now known to be multifaceted proteins that not
only link to structural gap junctional complexes, but also to
adhesion molecules, tight junctions, cytoskeletal elements,
and cellular machinery, which facilitates their transport,
assembly, function, and internalization. Initially, these gap
junction protein complexes were termed the “Nexus” [7],
which was the original structural name for the intracellular
links. This term has come back into use, alongside the term
“gap junction proteome” [8]. Once the gap junction channel
assembly has nucleated and further binding partners are
engaged, additional gap junction channels cluster and form
“gap junction plaques.” Cxs are a homogenous family of
proteins ubiquitously expressed in humans, and to date, 21
Cx genes have been reported in humans, and 20 in rodents.
3. ClinicalConnexins
Since the ﬁrst description of a mutation in the GJB1 gene
coding for Cx32 in patients with the X-linked Charcot Marie
tooth syndrome in 1993, disease-causing mutations have
been detected in almost every Cx gene [9, 10]. Patients
with the X-linked Charcot Marie tooth have an inherited
progressive peripheral neuropathy, characterised by distal
symmetrical neuropathy, muscle weakness, and sensory loss.
Within myelinating Schwann cells, Cx32 has been localized
totheparanodalregionsandSchmidt-Lantermannincisures,
which are found between the inner and outer layers of the
coiled up cell. Connexon hemichannels composed of Cx32
therefore enable the rapid transport of small molecules and
nutrients in a reﬂexive manner within individual Schwann
cells.AlthoughCx32isalsofoundoutsidetheperipheralner-
vous system in major organs like the liver, Cx32 mutations
are associated only with X-linked Charcot Marie tooth [11].
In the sections below, we will outline the various Cxs
associated with diabetes and its complications and discuss
relevant studies (both animal and human) in the current
literature.
3.1. Diabetes. Connexins are associated with the pathogen-
esis of both type I and type II diabetes (see Table 1)[ 12].
Cx36 forms the gap junctions between pancreatic beta cells
which are required for normal basal insulin secretion and
glucose-induced insulin release. Animal studies have shown
that loss of Cx36 is associated with the loss of pulsatile
insulin release, increase in basal insulin output, and reduced
glucose-induced insulin release (these secretory defects are
similar to those observed in type II diabetes) [13, 14]. The
e x a c tr o l eo fC x 3 6i nt y p eI Id i a b e t e si nh u m a n si sy e t
to be elicited. Cx36 is coded for by GJD2 gene, which is
located on the 14q region of chromosome 15, a susceptibility
locus for type II diabetes, and the diabetic syndrome [15].
Cx36 is a native protein of human pancreatic islets that
mediates the coupling of beta cells through preferential
exchangeofcationicmoleculesandcontributestothecontrol
of beta-cell function by modulating gene expression [16].
Endogenous glucose production is a major determinant
of fasting hyperglycaemia in type II diabetes [17]. Cx36
upregulation is associated with an increase in endogenous
glucose production, predominantly of hepatic origin. Both
Cx32 and Cx26 can form connexon hemichannels connect-
ing liver hepatocytes. In animal studies, these connexon
hemichannels are responsible for the regulation of blood
glucose and hepatocyte glycogenolysis [18, 19]. Following
electrical stimulation of sympathetic liver nerves, Cx32-
deﬁcient mice had ineﬃcient mobilisation of glucose from
hepatic glycogen stores [20]. The mechanism underlying
this dysregulation in hepatocytes may involve interaction of
Cxs with second messengers as Cx32-transfected HeLA cells
had increased transmission of inositol 1,4,5-trisphosphate-
mediated calcium waves to neighbouring cells [21].
Clinically, the complications of diabetes are vast. Due to
the almost ubiquitous tissue distribution of Cxs, there has
been interest in Cx changes in both diabetic macrovascular
and microvascular disease.
3.2. Macrovascular Complications of Diabetes. Cardiovascu-
lar complications are the leading cause of morbidity and
mortality in diabetes. Type II diabetes is an independent risk
factor for major large vessel atherosclerosis. In this section,
we will discuss the association of Cxs with atherosclerosis,
dyslipidemia, peripheral vascular disease, coronary artery
disease, hypertension, and arrhythmias.
Changes in the expression pattern of vascular Cxs (Cx37,
Cx40, Cx43, and Cx45) have been observed in animal model
studies during the formation of atherosclerotic plaques [22].
In atherosclerosis, Cxs may contribute to the inﬂammatory
responsethroughadhesionandtransmigrationofinﬂamma-
tory cells. Cx37 is thought to function in monocyte adhe-
sion and transmigration across the endothelium, whereas
endothelial Cx40 is implicated in transmitting antiadhesive
signals within the vascular endothelium [23].Cardiology Research and Practice 3
Table 1: Connexin changes associated with diabetic complications (upward and downward arrows indicate increase or decrease in Cx levels,
VECs: vascular endothelial cells, SMCs: smooth muscle cells).
Diabetic complication Connexin changes associated with diabetes Type of study References
Macrovascular
Atherosclerosis Early atheroma ↓Cx37 VECs and circulating monocytes Human and animal
diabetic studies [22]
Advanced atheroma ↑Cx37 SMCs, ↓Cx40 VECs
Early atheroma ↑then↓Cx43 SMCs
Advanced atheroma ↑Cx37, ↑Cx43 macrophage foam cells
Dyslipidemia ↓Cx37, ↓Cx40 VECs Human and animal
diabetic STZ rat studies [27, 28]
↑Cx43 VECs and SMCs
Hypertension ↑Cx40 VECs Animal studies (e.g.
Cx40−/− mice) [35–37]
↑Cx37, 43, 45 SMCs
Arrhythmias Ventricular myocytes ↑Cx43 (both total and phosphorylated forms) Animal diabetic STZ rat
studies [39–41, 43]
Atrial myocytes (↑Cx43 but ↓phosphorylated form)
Sinoatrial node ↑Cx45>↑ Cx43 and Cx45
Microvascular
Nephropathy ↓Cx37 renin secreting cells Animal diabetic STZ and
ZDF rat studies [44–49]
↑Cx40 SMCs preglomerular arterioles
↓Cx43 SMC postglomerular arterioles and mesangial cells
↑Cx43 collecting ducts, podocytes Human diabetic studies [50, 51]
Retinopathy ↓Cx43 retinal pericytes, microvascular endothelial cells Human diabetic cell studies [54–58]
Erectile dysfunction
Detrusor overactivity
↓Cx43 penile corpora
↑C x 4 3b l a d d e rd e t r u s o rm u s c l e
Animal STZ diabetic rat
studies [59–61]
Peripheral neuropathy ↑Cx26, ↑Cx32 perineurium Animal diabetic STZ rat
studies [62]
Wound healing ↓Cx43, ↓Cx26 epidermis Animal diabetic STZ rat
studies [70, 71]
↑Cx43 dermis, wound edge keratinocytes ﬁrst 24 hours after injury
↑Cx43 wound edge keratinocytes Human studies [72]
The in vivo eﬀect of diabetes on the expression pattern
of vascular Cxs within major large vessels is not fully under-
stood. The eﬀects of statins on connexin expression in the
arterial wall have been observed by Sheu et al. [24], who
observed reduced expression of Cx43 in diabetic rat aortic
walls and an increase in Cx43 levels following simvastatin
treatment. In contrast, Hou et al. [25] found that in apoE-
deﬁcient mice, STZ-induced diabetes was associated with an
increase in the burden of atheroma and downregulation of
endothelial Cx37 and Cx40 outside the plaque areas. The
downregulation of these endothelial Cxs was exacerbated by
short-term treatment with simvastatin. This study also raises
the issue of how Cx expression is altered in dyslipidemia.
In dyslipidemia, there is a reduction in Cx37 and Cx40 in
vascular endothelial cells and increase in Cx43 expression in
both vascular endothelial cells and smooth muscle cells. This
is supported by both hyperlipidemic mice studies by Yeh et
al. [26] who found reduced expression of endothelial Cx37
and Cx40 and human observational data. An association
between Cx37 polymorphism and peripheral arterial disease
in patients with type II diabetes has been observed [27]. Ani-
mal studies have also shown that treatment of dyslipidemia
reducesCxlevels.Dlugosov´ aetal.[28]identiﬁedCx43inthe
aorta (in both the tunica media and to a lesser degree in the
endothelium) of adult hereditary hypertriglyceridemia rats,
and that treatment with omega-3 polyunsaturated fatty acids
and atorvastatin markedly lowered Cx43 expression.
Atherosclerosis causes coronary arteries to progressively
stenose, and despite the development of drug-eluting stents,
restenosis is a serious clinical problem associated with signif-
icant morbidity and mortality. Diabetes still remains one of
the most important risk factors for restenosis following stent
implantation. The levels of Cx43 are increased in the smooth
muscle cells of atherosclerotic arteries of both humans and
mice [29–31]. Recent study of connexins following balloon
angioplasty has shown that this process is accompanied by4 Cardiology Research and Practice
elevated expression of Cx43 in endothelial cells and SMC
of the media and later the neointima [32, 33]. Neointima
formation following balloon catheter injury is signiﬁcantly
reduced in heterozygous Cx43 knockout mice (Cx43+/−),
suggesting a correlation between neointima formation and
high levels of Cx43 during the inﬂammatory response to
injury [34].
In humans, Type II diabetes is associated with hyperten-
sion, and animal studies have demonstrated that multiple Cx
changes are associated with the remodelling of the arterial
wall that occurs in response to hypertension. These Cx
changes are complex, and various expression patterns are
d e s c r i b e di nd i ﬀerent models of hypertension [35]. Renin
secretion is regulated by coordinated signalling between the
various cells of the juxtaglomerular apparatus and is de-
pendent on Cx40. Cx40 knockout (Cx40−/−) mice are ini-
tially found to be hypertensive [36]. Further studies [37]
using Cx40−/− mice have shown that chronic hypertension
upregulates Cx40 in endothelial cells, but Cx37, Cx43, and
Cx45insmoothmusclecells.ItishypothesizedthatforCx37,
Cx40, and Cx45, control of expression does not depend on
circulating plasma levels of renin and angiotensin II, but
these hormones are required for selective expression of Cx43
which may occur through angiotensin II activation of the
extracellular signal-regulated kinase and NF-κBp a t h w a y s .
As gap junctions mediate the cell-to-cell propagation of
current ﬂow that govern orderly contraction of the healthy
heart, there has been considerable investigation into the role
of Cxs (Cx40, Cx43, and Cx45) in arrhythmic diabetic heart
disease [38]. In rat studies of STZ-induced diabetes, there is
associated structural remodelling of Cxs (Cx40, Cx43, and
Cx45)inthesinoatrialnodeandventricularmyocytes,which
may partially account for sinus arrhythmias, ventricular
arrhythmias, and prolonged QT/QRS conditions found in
human diabetes [39, 40]. Inoguchi et al. [41] investigated the
underlying mechanisms by which Cx43 is involved in gen-
eration of arrhythmias in diabetic rat ventricular myocytes.
Increased levels of phosphorylated Cx43 were normalized by
useofaproteinkinaseCβ-speciﬁcinhibitor.Themechanism
proposed was that hyperglycaemia causes PKC activation,
which in turn causes phosphorylation of Cx43 and impaired
ventricular contraction. Associations between Cx43 and
dilated cardiomyopathy have also been identiﬁed. Mutations
in Lamin A/C gene (LMNA) causing dilated cardiomyopathy
are related to a decrease in Cx43 levels [42]. In these con-
ditions,itisthoughtthatthealtereddistributionofCxs(such
as Cx43) and consequent interruption of gap junctional
communication within the myocardium lead to decreased
velocity of electrical conduction, generation of reentry
arrhythmias, and arrhythmias causing sudden death [43].
3.3. Microvascular Complications of Diabetes
3.3.1. Nephropathy. Diabetic nephropathy is the commonest
cause of end-stage renal disease. In total, nine Cxs have
been found in the kidney (Cx26, Cx30.3, Cx31, Cx32, Cx37,
Cx40, Cx43, Cx45, and Cx46) [44–46]. In the preglomerular
vessels, cell-to-cell communication has an important phys-
iological role in the functional coupling between adjacent
nephrons supplied by a single interlobular artery. In rat
preglomerular renal microvasculature, there is extensive
expression of Cx37, 40, and 43 mRNA in endothelial cells
a n dC x 3 7m R N Ai ns m o o t hm u s c l ec e l l s[ 47]. In the
postglomerular renal microvasculature, only Cx43 is found
within the endothelial cells [44].
In diabetic nephropathy, early functional changes occur
in the nephron at the level of the glomerulus including
glomerular hyperﬁltration and hyperperfusion, before the
onsetofmeasurableclinicalchange.Overtime,furtherstruc-
tural changes like thickening of the glomerular basement
membrane, glomerular hypertrophy, and mesangial expan-
sion take place [48]. In animal models of diabetes, changes in
Cxsareassociatedwiththesekeypathophysiologicalfeatures.
Glomerular hyperﬁltration in early diabetic nephropathy
results from deceased resistance in both aﬀerent and eﬀerent
arterioles of the glomerulus. With the development of early
diabetic nephropathy in STZ rats, Hillis [44] found that
levels of Cx40 were increased in smooth muscle cells of the
preglomerular arterioles, while levels of Cx43 were decreased
in endothelial cells of the postglomerular arterioles. This
suggests that changes in these particular Cxs are associated
with impaired autoregulation and subsequent glomerular
hyperﬁltration. As discussed in Section 3.2 above, upregula-
tionofCx40inpreglomerularvesselsisofpathophysiological
signiﬁcance in animal models of hypertension, and normal
blood-pressure-controlled release of renin is dependent on
Cx40. The association between changes in Cxs and glomeru-
lar hyperﬁltration has also been studied in Zucker diabetic
fatty (ZDF) rats. Takenaka et al. [49] found that compared to
control rats, ZDF rats had glomerular hyperﬁltration. These
featureswereassociatedwithreducedCx37inreninsecreting
cells and enhanced phosphorylation of Cx43 (an event
that interfered with gap junction functioning). Aside from
the renal microvascular cells, glomerular mesangial cells,
which are normally found around the renal blood vessels,
are involved in the pathogenesis of diabetic nephropathy.
The studies in diabetic rats by Hillis [44] also showed
increasedCx37,Cx40andabsenceofCx43inbothextra-and
intramesangial cells. Later studies by this group [50] showed
that high glucose concentrations downregulated Cx43 and
promoted senescence of the glomerular mesangial cells.
Changes in Cxs in human kidney cells have been studied
in culture. Not all of the cell types have been studied, and
potential clinical applications require more consideration.
An interesting possibility is that Cx43 has a protective eﬀect
preventing renal damage. Hills et al. [51] studied human
collecting duct cell lines and observed that as glucose con-
centrationsincreased,therewasatime-dependentincreasein
the levels of Cx43. The increase in Cx43 and gap junctional
communication in response to high glucose was correlated
with functional acceleration of calcium transients between
cells. It was concluded that Cx43 may protect the collecting
duct from damage associated with established diabetic
nephropathy. Furthermore, levels of Cx43 have also been
studied in human diabetic nephropathy as a “predictive
marker” of disease progression and severity. Sawai et al. [52]
found that downregulation of Cx43 within podocytes was
closely associated with disease progression in establishedCardiology Research and Practice 5
diabetic nephropathy and correlated with the degree of
future decline in renal function.
3.3.2.Retinopathy. Throughoutthehumanretina,numerous
Cxs have been studied [53, 54]. Abnormalities in Cx
have been linked to the development of human diabetic
retinopathy. Inhumanpericytecellculturestudies byLietal.
[55], high glucose concentrations directly induced downreg-
ulation of Cx43 expression and inhibition of gap junctional
intracellular communication in retinal pericytes. Accelerated
apoptosis of retinal vascular cells is a key feature of diabetic
microangiopathy and is caused by inadequate transportation
of necessary cell survival and signaling molecules. Studies
of retinal microvascular endothelial cells have found that
decreasing Cx43 levels leads to a signiﬁcant increase in the
occurrence of apoptosis [56]. It has also been shown that
high-glucose-induced oxidative stress hyperphosphorylates
Cx43, leading to the disassembly of gap junctions and degra-
dation of Cx43 through the proteasome pathway [57, 58].
Diabeticretinopathyalsoisassociatedwithacceleratedapop-
tosis in retinal mitochondria. In the retinal mitochondria, it
has been shown that matrix metalloproteinase-2 activation
modulates the abundance of heat shock protein-60. This
is thought to then lead to opening of the mitochondrial
transition pores through disruption of Cx43 [59].
3.3.3. Erectile and Bladder Dysfunction. Patients with dia-
betes have a higher incidence of erectile dysfunction and
bladder dysfunction, and both these conditions are char-
acterised by early onset and increased severity. The role of
Cxs in the development of erectile dysfunction and higher
bladder detrusor muscle activity in diabetes is emerging
through recent animal studies. Suadicani et al. [60]f o u n d
markedly decreased expression of Cx43 in the penile corpora
and increased expression of Cx43 in the urinary bladder
following induction of diabetes in STZ rats. There is now
evidence that nitric-oxide-dependent mechanisms alone are
not suﬃcient for maintaining normal erectile function,
suggesting that other processes such as gap junctional com-
munication facilitate erectile function by enabling passage of
ions and small molecules necessary for the relaxation of cor-
poral smooth muscle cells [61] .I nb l a d d e rd e t r u s o rm u s c l e
overactivity, in addition to hemichannel paracrine signalling
mechanismsviaATPactivationofpurinergicreceptors,other
potential mechanisms that could be responsible for bladder
dysfunction include transcriptional regulation of Cx43 by
basic ﬁbroblast growth factor (bFGF), and signaling via the
ERK-AP-1 pathway [62].
3.3.4. Peripheral Neuropathy. Diabetic peripheral neuropa-
thy involves both somatic and autonomic nerves, causing
sensory deﬁcits, palsies, and cardiovascular, gastrointestinal,
and genitourinary dysfunction. The initiation of diabetic
peripheralneuropathyisnotwellunderstood.Variousmech-
anisms are involved in the pathogenesis of this condition,
including terminal nerve destruction, decreased neuronal
conductance, demyelination, microvascular insuﬃciency,
inﬂammation, and oxidative damage. As discussed above,
Cx32 gene mutation in humans is strongly associated with
peripheral neuropathy in X-linked Charcot Marie tooth
disease. It is also known that gap junctional communication
is important in the maintenance of the perineurium blood-
nerve barrier. Reduced levels of Cx32 and 26 have been
observed in the perineurium in STZ rat model of diabetes-
related peripheral neuropathy and are likely to contribute to
this condition [63].
3.3.5. Chronic Ulceration. Diabetic patients are more prone
to develop foot ulcers, for several reasons including neuropa-
thy, vascular disease, and foot deformities [64]. Diabetic foot
w o u n d sa r ev e r ys l o wt oh e a l[ 65], and numerous dysfunc-
tional events occur in all phases of diabetic wound healing
(acute inﬂammation, proliferation, and remodelling). There
is impairment of the inﬂammatory response, macrophage
function, cytokine, chemokine and growth factor produc-
tion, extracellular matrix production, angiogenesis, kerati-
nocyte, and ﬁbroblast migration and reepithelialisation [66].
At least ten of the Cxs are found within the skin (Cx
26, 30, 30.3, 31.1, 32, 37, 40, 43, and 45) [67]. However,
the spatial and diﬀerential expression pattern of Cxs in
the skin does vary between animals and humans [68]. In
humans, Cx43 is the most abundant Cx of the epidermis,
expressed throughout the spinous, granular, and basal cell
layers,sebaceousglands,hairfollicles,andbloodvessels[69].
Cx26 is less abundant in the epidermis and is found in a
patchy distribution in the basal keratinocytes, but is highly
expressed in hair follicles and sweat glands [70]. In animal
models, when diabetes is induced, there are signiﬁcantly
altered Cx levels in various layers of the skin in response
to injury. Studies by Wang et al. [71] demonstrated that
in the skin of rats with STZ-induced diabetes within two
weeks of the onset of diabetes, Cx43 and Cx26 proteins
were signiﬁcantly downregulated in the epidermis, whereas
Cx43 was upregulated in the dermis. These ﬁndings indicate
thatdiabetesdoesnotuniformlyrepressconnexinexpression
throughout the layers of the skin, but can also enhance it.
Furthermore, after wounding in diabetic rats, the wound
edge keratinocytes upregulate Cx43 in the ﬁrst 24 hours
after injury. The keratinocytes then form a thickened bulb
of nonmigrating cells at the wound margin and do not start
migrating until Cx43 downregulates, around 48 hours after
wounding. This increased level of Cx43 then delays reep-
ithelialisationandthewound-healingprocess.Preventingthe
abnormal expression of Cx43 in wound edge keratinocytes
rescued wound healing to normal rates or even better [70].
If Cx43 expression in human diabetic wounds is altered in
a similar way to the STZ diabetic rat model, targeting Cx43
may provide a new clinical application for the treatment of
diabeticulceration.Qiuetal.[72]initiallystudiedthetopical
application of a Cx43 antisense olidodeoxynucleotide (Cx43
asODN) pluronic gel to murine wounds. This treatment had
a rapid eﬀect, noticeable as early as six hours after injury.
The treated wounds appeared less erythematous and oede-
matous, with reduced exudate and less gape than control
wounds. In diabetic STZ rats, Kamibayashi et al. [70] also
found that the application of Cx43 asODN pluronic
gel inhibited the upregulation of Cx43. This treatment6 Cardiology Research and Practice
signiﬁcantly improved wound healing, compared to control
wounds, doubling the rate of reepithelialisation.
Inhumandiabetic ulcerbiopsies, Brandneretal.[73]has
reported persistence of Cx43 expression in wound-edge ker-
atinocytes. Other studies of human diabetic ﬁbroblasts have
also shown increased gap junctional communication, which
correlated with reduced cell proliferation [74]. Overall, Cxs
are associated with tissue response to injury directly, via gap
junctional communication, and may also contribute to the
wound repair process indirectly [75]. The downregulation
of Cx43 may have direct eﬀect on the migratory ability of
the cells involved in wound healing, through its central role
in the protein “nexus.” Cx43 downregulation may also exert
an inﬂuence at the transcriptional level on numerous other
genes and proteins [76].
4. Conclusion
The study of Cxs in diabetes is of interest. The changes in
Cxs found in diabetes are associated with both direct eﬀects
within the vasculature and indirect eﬀects, by impairment
of homeostasis in vital organs such as the liver and kidney.
It is unlikely that targeting individual connexins will cure
diabetes. However, it may be possible to alleviate some of the
symptoms of microvascular complications, as demonstrated
in recent work using topical Cx43 asODN gel treatment. As
considered in nephropathy studies, Cxs may also be used as
future predictors of both diabetes progression and severity.
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